Testosterone measurements that are accurate, reliable, and comparable across methodologies are crucial to improving public health. Current US Food and Drug Administration-cleared testosterone assays have important limitations. We sought to develop assay performance requirements on the basis of biological variation that allow physiologic changes to be distinguished from assay analytical errors.
Several publications demonstrate that both past (1 ) and present testosterone assays have important limitations, especially when used to measure concentrations in women and children (2) (3) (4) (5) . According to the data of these studies, testosterone immunoassays can have errors ranging from 200% to 500% compared with mass spectrometry-based measurements. These publications led to an Endocrine Society position paper (6 ) and the development of a consensus statement endorsed by 11 scientific, medical, and laboratory organizations with the stated purpose of improving "the quality of research, patient care, and public health through broad implementation of standardized testosterone results that are accurate, reliable, and comparable over time" (7 ) . To sustain these initial efforts to improve testosterone assays, a coalition of 13 organizations was formed. 10 The Partnership for the Accurate
Testing of Hormones (PATH) 11 (initially known as the Coalition for Quality Testing) is pursuing several strategies to improve the state of testosterone testing, including the ongoing examination of performance criteria for assays. These performance criteria for minimizing variability of measurement results should be sufficient to ensure the comparability of measurement results over time and across different assays and laboratories. Comparability of test results performed in research studies is vital for interpretation of research findings and the investigation of public health problems. Comparable testosterone results are also essential for effective patient care. Understanding the strengths and limitations of current testosterone tests, such as assay specificity, sensitivity, precision, and accuracy, is important when choosing an assay for clinical application. An understanding of biological variability and other factors affecting testosterone concentrations is also required to distinguish normal biological variation from a true physiological change. This article addresses 1 aim of the PATH: to develop desirable analytical performance criteria for testosterone assays. Improvements in the accuracy, precision, and comparability of testosterone measurements in serum and plasma are clearly needed and should address analytical issues as well as preanalytical variability.
Setting goals for analytical quality can be based on various principles. At a conference on "Strategies to Set Global Analytical Quality Specifications in Laboratory Medicine" in Stockholm 1999, a hierarchy of models to set analytical quality specifications was determined (8 ) . The conference consensus defined the highestlevel criterion for setting quality specifications as that based on the effect of analytical performance on clinical outcomes in specific clinical settings. This criterion requires that a test be used in a single, well-defined clinical situation and that widely accepted medical strategies be instituted based on the analytical result, a case that does not apply currently to testosterone measurements, since these measurements are used to diagnose a variety of conditions in men, women, and children (9 ) . The second-level criterion of determining assay specifications was based on components of biological variation. The conference also recognized minimal, desirable, and optimal analytical performance (10 ) . The biological approach of setting analytical quality specification attempts to minimize analytical variability so that changes in patient values can be attributed to biological or physiological change (11, 12 ) .
Using biological variation to derive analytical performance criteria begins with determining how much natural variation is expected for a test result. The concentration of measurand in individuals varies around their baseline or homeostatic set-point. The total variation observed is composed of preanalytical variation, analytical variation (imprecision and bias), and inherent within-person biological variation. In a laboratory setting, we can control preanalytical and analytical variability, leaving the biological component as the only true variable. If preanalytical error related to phlebotomy, transport, handling, and storage of samples is minimized, and the analytical variation is considerably less than the biological variability, serial testing can be used to determine whether a patient has improved (11, 12 ) . Determining the effect of analytical variation relative to biological variation is a straightforward way to develop desirable performance criteria of an assay (10, 13 ) .
The amount of analytical error added to biological variability can be calculated from the ratio of the analytical coefficient of variation (CVa) to the withinperson CV (CVi). For these purposes, the CV is defined as the SD divided by the mean of a measurement. If the CVa is less than one-half the average within-person variation (considered as a desirable analytical performance), then this will not increase the total error of a test result Ͼ12% (11, 14 ) . As CVa rises, the amount of added error is nonlinear. For example, when CVa Ͻ0.75 CVi (considered as a minimal analytical performance), then at most 25% variability is added; but when CVa Ͻ0.25 CVi (optimal analytical performance), then a maximum of 3% variability is added (13 ) .
When a test result is applied to the diagnosis of disease, results are usually compared with a population-based reference interval. In this case, analytical goals depend on both bias (difference from truth) and imprecision (CVa). The dispersion of the reference interval is based on the underlying biological distribution of the reference population in addition to the analytical variability. Reference intervals are generally defined as the central 95% of the reference population distribution, which means that 2.5% of the results will lie below the lower reference limit and 2.5% will lie above the upper reference limit. A positive analytical bias will increase the percentage of results outside the true upper reference limit and decrease the percentage outside the lower reference limit (15 ) .
In this article, we develop performance criteria for testosterone assays in terms of minimal, desirable, and optimal performance on the basis of existing published data, primarily obtained using immunoassay-based methodologies.
Materials and Methods
Two PubMed literature searches were performed to identify articles associated with biological variation of testosterone measurements. identified a total of 65 articles. The second literature search was based on the key words (all fields) "testosterone", "biological variation", and "human". PubMed 1966 -2011 revealed a total of 198 articles. Any duplicate articles from the previous searches were removed to produce a final list for inclusion. We were particularly interested in identifying papers with data on CVi and between-person biological variability (CVg). We did not find any articles that contained CVi and CVg data for children. For women, we found only 1 article with CVg data. When evaluating journal articles, we followed the model described by Ricos et al. (16 ) , which grouped publications on the basis of mathematical models used to describe components of variation. Publications in group 1, which did not use widely accepted methods for calculating variability, were deleted from subsequent analysis. Groups 2, 3, 4, and 5, where the CVs were calculated using manual methods, ANOVA, or mixed effects model and CVa was less than CVi, were included in our analysis of biological variability. Among the 13 articles that presented data of biological variation, 9 were excluded at this step. Four articles met our acceptability criteria and were used to calculate analytical performance goals.
Performance criteria were based on previously published formulas for minimal, desirable, and optimal imprecision and bias (10, 13 ) . Analytical imprecision (CVa) goals for minimal, desirable, and optimal performance were 0.75CVi, 0.5CVi, and 0.25CVi, respectively (10 -11 We evaluated the performance of currently available testosterone assays in recent College of American Pathologists (CAP) surveys using the analytical performance criteria developed in this article. We evaluated the CAP accuracy-based survey (ABS) (2011 CAP data of ABS-01, ABS-02, ABS-03, and ABS-04 samples). Bias and imprecision were evaluated relative to a target value based on the CDC reference method and interlaboratory SD representing within-peer (group) variability, respectively (Fig. 2) . We included only peer groups of n Յ 10, the minimum number required for precision data included in CAP reports.
Participants in the CDC Laboratory/Manufacturer Hormone Standardization (HoSt) program are challenged with 10 samples on 4 different occasions in 1 year (n ϭ 40). These samples include 20 male and 20 female individual samples with testosterone concentrations assigned based on the CDC reference method. The 40 samples are analyzed by participants in duplicate on 2 separate days by each assay (n ϭ 4 for each sample), for a total of 160 measurements. As a starting point, the CDC HoSt Program uses only an overall mean bias of Ϯ6.4% as a performance criterion to evaluate and certify participants as being sufficiently accurate. Of the 11 participants that were enrolled in this program in 2010 and completed 4 consecutive challenges, 73% were able to successfully meet this criterion. At the time this article was written, 8 laboratories met the Ϯ6.4% CDC performance criteria. In keeping with the Clinical Chemistry policy that requires all laboratories to be identified (17 ), we asked the 8 laboratories if they would be willing to share their data for publication. Of the 8 approved laboratories, 5 laboratories agreed to share their data for this publication. Data from the selected laboratories that successfully completed the CDC HoSt Program were included to evaluate current performance against our new recommendations for imprecision, bias, and total error for individual measurements. Table 3 shows the percentage of individual measurements reported by participants that met the desirable and minimal performance criteria of imprecision, bias, and total error. Imprecision is the CV of the 4 individual measurements of each sample, and bias is the percent difference between the mean of 4 replicate measurements and the assigned value. Total error is the percent difference between the individual measurement of each sample and the assigned value (n ϭ 160).
Results
We derived the required analytical performance criteria for testosterone measurements from published CVi and CVg data. Thirteen articles from 8 countries contained data for both CVi and CVg. These manuscripts were considered for determining analytical performance criteria. All articles in which the analytical CV was higher than the within-person CV (1 study), or in which the mathematical model was classified as group 1 (8 studies) were excluded from the final analysis, resulting in the 4 articles listed in Table 1 . We used data extracted from the articles in Table 1 to determine the analytical performance goals for serum testosterone measurements summarized in Table 2 . The desirable analytical imprecision and bias are 5.3% and 6.4%, respectively. The total error goal based on the maximum desirable bias and imprecision is 16.7%. Plots in Fig. 1 show the desirable analytical goals and the possible total error budget for testosterone measurements as a percentage (Fig. 1A) , near the lower limit of the reference interval in men [300 ng/dL (10.4 nmol/L)] (Fig. 1B) , and near the upper limit of the reference interval for samples from women [30 ng/dL (1.04 nmol/L)] (Fig. 1C) . The dotted line in Fig. 1 is calculated by use of the desirable total error (16.7%) and uses a 2-distribution [TE ϭ bias ϩ (1.96 ϫ CVa)].
Data for total error obtained from recent CAP proficiency surveys plotted against the desirable error are shown in Fig. 2 . Each data point in the figure represents a different immunoassay and is based on at least 10 responses from different laboratories. Fig. 2, A-D Fig. 2 are based on immunoassay-based platforms and demonstrate that most of the assays miss the analytical goals by wide margins. We did not include the mass spectrometry data for the CAP survey in Fig. 2 because there were an insufficient number of laboratories to calculate precision. Despite the insufficient number (Ͻ10) of laboratories that use mass spectrometry to calculate precision, the mean of the mass spectrometry-based assays met the desired bias requirement in 2 of the 4 CAP samples. Table 3 tabulates the percentage of samples from selected laboratories that successfully completed the HoSt program (overall mean bias of Ϯ 6.4%) and met desirable and minimal performance criteria described in this article. As can be seen from this table, performance of the different certified assays on individual samples, obtained from a mix of both males and females, varied widely in terms of imprecision, bias, and total error. For assay D, only 55% of the samples met the desirable imprecision criteria, whereas 97% of samples analyzed by assay C met the desirable imprecision criteria. Desirable bias results were similar, with a low of 54% of samples for assay C and a high of 98% for assay A. Desirable total error ranged from 67% to 100% of samples analyzed.
Discussion
The analytical goals developed in this article are similar to the analytical performance criteria suggested by Ricos et al. in 1999 (16 ) and updated at Westgard QC (http://www.westgard.com/biological-variationdatabase-specifications/print.htm) (18 ) . Desirable specifications for imprecision, bias, and total error as derived from biological variation at Westgard QC are 4.7%, 5.4%, and 13.1%, respectively (18 ) . The similarity of these results with ours may have occurred because among the 4 articles (19 -22 ) used for calculating analytical goals in our study, 2 (19, 21 ) were the same as those of Westgard QC. In our literature review, 2 new studies were found that contribute to our understanding of CVi and CVg for testosterone (20, 22 ) .
Data from the CAP study shows that many routine methods miss the desirable analytical goals of our study by wide margins. In the analysis of 2011 CAP ABS data using commutable materials, most assays revealed high bias [range, Ϫ178.3 to Ϫ61.6 ng/dL (Ϫ6.19 to Ϫ2.14 nmol/L) (Ϫ32% to Ϫ11%)] and imprecision (interlaboratory CV, 3.8 -9.2%) at a target value of 558 ng/dL (19.4 nmol/L) (Fig. 2B) . For a target value of 37.6 ng/dL (1.31 nmol/L), the magnitudes of bias [range, Ϫ6.1 to 8.2 ng/dL (Ϫ0.21 to 0.28 nmol/L] (Ϫ16% to 22%)] and imprecision (interlaboratory CV, 14.8 -25.9%) were also high (Fig. 2C) .
To optimize performance of testosterone assay measurements, both imprecision and bias errors need to be improved. When diagnosing patients according to a population-based reference interval, analytical bias can lead to the misclassification of patients. To minimize bias, traceability is needed. The CDC HoSt program is designed to improve imprecision, bias, and total error. If all assays were traceable to a reference method, the bias error should improve. Imprecision is method dependent. Improving precision depends on having robust analytical methods that are well validated. Tools such as designated comparison methods with commutable human samples should allow for improvements in interlaboratory harmonization.
All the assays shown in Table 3 met the initial CDC criteria of an overall mean bias of Ϯ6.4% for both male and female samples. This initial criterion is based on existing data published by Ricos et al. (Westgard QC, http :// www.westgard.com/biological-variation-database- specifications/print.htm). The mean bias is used to determine and minimize calibration bias of individual assays. Although it improves calibration bias and reduces interlaboratory variability, this process does not necessarily improve variability caused by other sources. Variability from other sources can be described by the scatter of individual measurement results around target values of individual samples. This scatter can be substantial, indicating that individual measurement results can deviate greatly from the target value. This is an important consideration, as individual measurement results are used in patient care. Thus, it is also critical that assays perform well for each individual measurement. The data in Table 3 show that most of the currently approved CDC assays meet our recommended minimal total error criterion (25%) with the exception of assay C. Table 3 also demonstrates that the desirable level of performance we describe is achievable for total error, as 100% of assay A samples met the desirable total error criteria of 16.7%. It is worth noting that the data presented in Table 3 comprise only selected certified laboratories meeting the CDC 6.4% mean bias criteria and probably represent the best-case scenario. We believe that the data in Table 3 demonstrate what some of the best laboratories are currently capable of and confirm that our analytical goals are achievable. It is worth noting that mass spectrometry-based assays, when taken as a mean, only met the bias criteria in 2 of 4 samples on the CAP ABS. As has been pointed out previously, simply implementing a mass spectrometry-based assay does not equate with accuracy and precision (23 ) ; it is essential that all assays are rigorously validated. Of the 5 assays currently certified by the CDC, 4 are based on mass spectrometry, with assay C being the only immunoassay that currently passes the CDC 6.4% bias criteria.
A limitation of this manuscript is that our analytical goals are based on a small number of studies (n ϭ 4) in a small number of young men (n ϭ 54). Insufficient published data exist for testosterone CVi and CVg in older men, women, and children. Because it is important to accurately measure testosterone concentrations across a wide range of values [e.g., 2-2000 ng/dL (0.069 -69.4 nmol/L)], we recommend that the available data on CVi and CVg be used to calculate performance criteria across the range of expected values. We also recommend that additional studies be conducted to obtain CVi and CVg data from a large number of research participants including older men, women, and children using certified reference methods. Based on these data, necessary revisions can be made to the analytical performance criteria. An additional limitation of this manuscript is that the compiled database of biological variation was based mostly on direct immunoassay methods. Owing to possible specific- ity problems with these assays, the measured interperson variability is likely greater than the true value.
